Recent systematic reviews note >40 studies that address frailty in patients with cardiovascular disease published between 2010 and 2014. 2, 4, 5 Research has primarily focused on the association between baseline frailty and both shortterm 6 and long-term 7 mortality after an event or procedure. 2, 4, 5 Other outcomes considered include disability, 8,9 cardiovascular events, 10,11 and institutionalization, 12,13 as well as the association between frailty and cardiovascular risk factors. [14] [15] [16] Few studies have focused on frailty as a primary outcome and described it over time in cardiovascular patients. 16, 17 Frailty scores are generally higher in women than men 18,19 and rise exponentially with increasing age. 20-22 Frailty trajectories may also vary by the type of coronary treatment (ie, coronary artery bypass graft [CABG] surgery, percutaneous coronary intervention [PCI], or medical therapy only [MT]) patients receive. Although a cardiac intervention might lead to an improvement in the person's frailty status by improving their Background-Frailty is an independent risk factor for cardiovascular outcomes. However, its trajectory after coronary artery disease treatment is unknown. Methods and Results-Three hundred seventy-four patients undergoing nonemergent cardiac catheterization followed by treatment (ie, 128 coronary artery bypass graft [CABG], 150 percutaneous coronary intervention [PCI], 96 medical therapy only) were observed for 30 months. A frailty index (FI) score was calculated at baseline (before initial treatment) and 6, 12, and 30 months after treatment. Random-effects models compared FI score trajectories by sex, age, and treatment group. Mean baseline FI scores were 0.170, 0.154, and 0.154 for CABG, PCI, and medical therapy only, respectively. FI scores decreased (improved) 6 months after initial treatment, then increased (worsened) at 12 and 30 months (P<0.001 for differences over time). Women had nonsignificantly higher FI scores than men (P=0.097) but followed the same trajectory (P=0.352 for differences over time). In patients aged ≥75 years, FI scores increased postbaseline for CABG and medical therapy only and after 6 months for PCI patients. Patients <75 years assigned to PCI and CABG experienced a sustained frailty reduction, whereas those assigned to medical therapy only showed stable frailty over the 30-month follow-up period (P value for differences over time by age and treatment group=0.041).
S ignificant improvements in survival rates among patients with coronary artery disease (CAD), including those aged ≥75 years, have led to a greater focus on functional and quality of life outcomes. 1 In this area, the concept of frailty has attracted increased attention as a means of identifying patients more prone to worse outcomes with coronary care. 2 Bergman et al 3 defined frailty as enhanced vulnerability to stressors because of impairments in multiple, interrelated systems that lead to decline in homeostatic reserve and resilency. Understanding the dynamic nature of frailty may assist healthcare providers in providing more appropriate patient care for the entire course of management.
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clinical symptoms, a more invasive procedure might also precipitate the onset or the deterioration of their frailty status. [23] [24] [25] Using data from cardiac patients undergoing coronary angiography at a tertiary care center, we sought to determine the patterns of frailty change postprocedure and the influence on frailty trajectories of the sex, age, and treatment group of patients.
Methods

Study Design and Sample
This was a substudy of the Calgary Cardiac and Cognition (3C) Study, a prospective cohort investigation of the effect of physical, neurocognitive and psychological factors on health outcomes and functional recovery in older patients undergoing coronary treatments. 26 Three hundred seventy-four subjects aged ≥60 years were enrolled between October 2003 and February 2007. All underwent coronary angiography for CAD at an urban tertiary care hospital providing centralized cardiac services for southern Alberta. Recruitment was stratified according to 3 initial treatments assigned after the coronary angiogram: CABG (n=128), PCI (n=150), and MT (n=96). Potential participants were excluded if they underwent an emergency catheterization, had previous revascularization, or were unable to complete the assessment because of language difficulties or mental or physical impairments. Ethical approval was received from the Conjoint Health Research Ethics Board, University of Calgary, and participants provided informed consent.
Trained research nurses and associates administered a standardized assessment battery collecting neuropsychological and physical performance, sociodemographic, health behavior, activity of daily living, and health-related quality of life measurements at baseline (preprocedure) and 6, 12, and 30 months after the procedure. The 3C database was linked with the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH), 27 a registry of all patients undergoing cardiac catheterization in the province, for baseline clinical information. Three patients could not be linked because of out-of-province catheterizations (n=2) or missing linkage (n=1). Blood samples were collected for 357 of the 374 participants (95.5%) at the time of catheterization for patients receiving MT or at the time of revascularization for patients who underwent PCI and CABG. Figure 1 illustrates the subject flow for 3C. 26 Retention of participants was 89% during the course of the study. All patients were categorized according to their originally assigned treatment group.
Frailty Index
The outcome, frailty index (FI) score, was used because it is a widely employed, validated approach to the assessment of frailty 28 that is flexible in its implementation. 29, 30 Also, as a continuous measure, it would be expected to be more sensitive than a categorical one for assessing change over time. An FI is the proportion of age-related health deficits an individual has accumulated. A deficit can be any disease, symptom, laboratory abnormality, or a functional or cognitive impairment associated with health decline that accumulates but does not saturate with age. [29] [30] [31] The index does not require a prespecified list of deficits as variables but can be implemented by anyone using any list of potential deficits, provided that they are at least 40 in number and that they come from a wide range of domains (physical, cognitive, disability, comorbidity, emotional, and social). 30 Individual frailty is scored as a proportion of actual deficits divided by total possible deficits, a decimal number between 0 and 1. The FI score is higher when there are more deficits. [29] [30] [31] A higher FI is associated with an increased risk for institutionalization and short-term mortality. 29, 30 In 3C, 53 potential deficits were derived from the clinical assessments, APPROACH data, and blood work obtained on participants, based on the criteria described above. Our selection covers a range of systems: physical, cognitive, emotional, health-related quality of life, disability, and medical condition, 30 and are described in Appendix A in the Data Supplement. The FI score was calculated as the number of deficits present in an individual divided by the number of potential deficits where data were available (ie, <53 if the data were not complete).
Statistical Analysis
Descriptive analyses were conducted to compare baseline sociodemographic and clinical characteristics by treatment group and across visits. To compare change by initial level of frailty, categories were created, the first 4 of equal width (0.06 in FI score), and all scores >0.24 for the last category. Equal-ranged categories were used, rather than sample-derived quintiles, to better compare the distribution and movement of data over time by comparing equal-sized ranges. For each of 3 transitions (baseline to 6 months, 6 to 12 months, and 12 to 30 months), proportions were estimated for FI score decrease (≥0.02 decrease in FI score), stable FI score (change of <0.02), FI score increase (≥0.02 increase in FI score), deaths, and withdrawals. 32 A change of 0.02 was used as it corresponds with slightly more than a gain or loss of one deficit and is similar to the threshold used by other researchers. 33 To compare age, sex, and treatment group differences associated with change over time, we fitted FI scores to linear mixed models with a random intercept. Visit was modeled as a repeated categorical measure to accommodate a possible nonlinear relationship between
WHAT IS KNOWN
• Frailty is a dynamic, independent risk factor for cardiovascular outcomes. • The frailty index (FI) is a valid, continuous measure of the severity of frailty, which has been frequently used in later-life frailty research.
WHAT THE STUDY ADDS
• After the initiation of coronary artery disease therapy, the trajectory of FI scores followed a U-shaped curve where frailty temporarily decreased but then increased after 6 months to 1 year. • However, patients ≥75 years of age assigned to coronary artery bypass surgery or only medical treatment did not on average experience this reduction in their frailty severity with treatment. • Patients ≥75 years of age, coronary artery bypass surgery patients, and women trended toward higher FI scores overall compared with other subgroups. score and time. For the age comparison, age was categorized into quartiles based on the sample distribution, to isolate the oldest and youngest quartiles. For the age by treatment group comparison, 2 categories were used, ≥75 and <75 years, as the 3 lower age quartiles had similar results and were combined. Models were adjusted by age, sex, and education as appropriate because all have associations with frailty criteria. [18] [19] [20] [21] [22] 34 Ethnic differences were not examined because 95% of the sample was of European or unknown ethnicity. Adjusted least-square means (ie, predicted marginal means estimated over a balanced population), their standard errors, and accompanying P values based on the tests of fixed effects 35 were recorded for each model. A P value is given for change in score across visits, for mean score differences between groups overall, and for differences between groups in mean score changes across visits. Residuals were reviewed to check on assumptions of homoscedasticity and normal distribution. SAS 9.4 (SAS Institute, Cary, NC) was used for all analyses.
Results
Baseline Characteristics
The study sample was 26.7% female, with an average age of 71.4 years ( Table 1 ). The MT group had a significantly higher proportion of women (39.6%) compared with the PCI group (27.3%) and CABG group (16.4%). The CABG group had a significantly higher proportion of patients with stable angina (74.4%), high-risk coronary anatomy (90.4%), and diabetes Table 2 describes the proportions of the sample that increased, decreased, or maintained their FI score (±0.02) during each transition period. This is stratified by FI score at the beginning of each time interval. Overall, a greater proportion of FI scores decreased (ie, frailty levels improved) from baseline to 6 months, whereas a greater proportion of FI scores increased (ie, frailty levels worsened) during the later time intervals. The groups with the highest frailty levels (FI scores of 0.24+ and 0.18-0.24) were the most dynamic, with under a third maintaining stable FI scores during any transition period. By contrast, two-thirds of the 2 most robust groups maintained stable FI scores across any time interval. In the first 6 months postinitial treatment, there were more deaths in the highest frailty levels (>0.18), but no obvious pattern was observed during subsequent time intervals. Figure 2 and Tables 3, 4 , 5, and 6 present the adjusted mean FI scores at baseline, 6, 12, and 30 months postprocedure for the group overall and for 4 subgroup categories: (1) sex, (2) baseline age category, (3) initial treatment group, and (4) baseline age (≥75 years) by treatment group. Overall, the mean FI scores followed a U-shaped curve, with scores declining after the initial treatment and rising thereafter (P<0.001 for differences over time). As illustrated in Figure 2A and Table 3 , women showed a nonsignificantly higher mean FI score than men across all visits (P=0.097). For both sexes, the change in the FI score over time followed a U shape with an initial decline from baseline followed by an increase postprocedure. This change over time was statistically significant (P<0.001). Male and female trajectories did not differ from each other (P=0.352).
Proportions Showing Increases or Decreases in FI Score Over Time Intervals by Initial FI Score
Frailty Trajectories by Sex, Age, and Treatment Groups
Frailty differed by age group overall (P<0.001), with older age groups showing consistently higher mean FI scores than younger ones across all visits ( Figure 2B ; Table 4 ). FI score trajectories also differed by age group (P<0.001), with the †Based on an annual rate of increase of 3.5% in community-dwelling persons. This is the baseline frailty index score times 1.09 (=1.035 2.5 ). 22 oldest quartile (75+) failing to show the early improvement observed in the younger age groups. Overall, 3C participants who underwent CABG as their initial treatment trended toward higher mean FI scores across all visits than those who underwent PCI or received MT only (P=0.053; Figure 2C ; Table 5 ). U-shaped curves were observed for both PCI and CABG groups. For the PCI group, the decrease in mean FI score was greater at 6 and 12 months. FI scores were still slightly lower than baseline at 30 months. For the CABG group, the decrease in mean FI score was not as great at 6 and 12 months, and the score at 30 months was greater than baseline. By contrast, the mean FI score for patients assigned to MT tended to increase over time. However, the P value for treatment differences in FI score trajectories was 0.090.
Treatment group trajectories did not vary by sex (results not shown, P=0.579); however, they did vary by age ( Figure 2D ; Table 6 ). Specifically, mean FI scores for CABG patients aged <75 years decreased in months 6 and 12, but mean FI scores for CABG patients aged ≥75 years increased steadily from baseline. Similarly, mean FI scores increased steadily for MT patients aged ≥75 years, whereas mean FI scores for those aged <75 years did not. Mean FI scores declined from baseline to 6 months for all PCI patients regardless of age. However, after month 6, mean FI scores increased for those aged ≥75 years receiving PCI but not for the younger PCI group. These age differences between treatment groups in change over time were statistically significant (P=0.041).
The seventh column of Tables 3, 4 , 5, and 6 shows what the mean FI score would have been if the rate of increase from the baseline score had been 3.5% per year, as observed in adult, community-dwelling populations who do not necessarily have cardiovascular disease. 22 In comparison with the adjusted mean FI scores at 30 months, patients overall had a lower average FI score than would be expected (0.169 compared with 0.178). Looking at the subgroups, those who had lower FI scores than would be expected were men, those <75 years of age, and those who had CABG and PCI. Those >75 years with CAD become frailer at a faster rate than predicted for community-dwelling seniors regardless of treatment assignment. This comparison is speculative as we are comparing patients with CAD to a general population, but it does provide context to the rate of change within this sample.
All analyses done using the FI were also performed using a frailty screening tool developed on the study sample. 36 Similar patterns with regard to sex, treatment, and age differences were observed. These results are not shown but are available on request.
Discussion
This is one of the first studies to determine frailty in patients before and after implementation of invasive therapy (CABG and PCI) or assignment to MT for CAD. It provides a guide as to the anticipated frailty trajectory for patients diagnosed with and treated for CAD. Frailty took on a U-shaped trajectory for the whole sample. However, different patterns emerged within particular age and treatment groups. Trends did not vary based on initial frailty status. However, frailty was more dynamic in frailer groups as the 2 frailest categories had the smallest proportion with stable FI scores across any of the 3 intervals. Older participants were less likely to experience an improvement in frailty after implementation of their treatment plan and tended to have steeper increases than younger age groups. This is also consistent with literature that describes an exponential relationship between frailty and age. [20] [21] [22] The interaction between age and treatment plan has important implications for individual patient care. Despite significant improvements in survival for CAD patients undergoing coronary treatments, including older patients, these differences may impact important functional and quality of life outcomes. For example, the negative effects of hospitalization, because of prolonged loss of mobility, may impact older age groups more than younger groups, overriding health improvements after CABG and leaving a patient with a reduced resilience. [23] [24] [25] 37 Consistent with the literature, women trended toward higher FI scores than men. 18, 38 However, men and women followed parallel courses during the 30-month period, and treatment group differences did not vary by sex. Some researchers have asserted that in the general population, women have less risk of unfavorable outcomes than men at similar frailty levels. 29 Others have concluded that women have more risk because of higher frailty measurements. 18 Previous research has found sex differences in acute coronary syndrome presentation and outcomes, which could not be accounted for by baseline clinical differences. 39 The inclusion of frailty measures may help to account for some of these differences.
Numerous publications have looked at frailty longitudinally in general populations: characterizing frailty transitions, 22, 32, 33, 40 examining potential predictors of transitions, [41] [42] [43] testing interventions to limit worsening frailty, 44 and comparing static versus dynamic frailty measures to predict functional decline. 45 However, few have looked longitudinally at a cohort of patients with cardiovascular disease. A literature search revealed only one previous study looking at frailty at more than one time point in patients with cardiovascular disease. Myers et al 17 categorized an FI at baseline postacute myocardial infarction and 10 to 13 years postbaseline using 32 variables and found an association between the 2 FI measurements with mortality. Our study made use of the FI as a continuous measurement and focused on describing the trajectory of frailty as patients progressed from treatment through recovery and beyond.
Study Strengths and Limitations
A particular strength of our study is the large clinical sample, the detail of repeat measurements, and the 30-month length, relative to other clinical prospective studies that examined cardiovascular interventions. We compared 3 treatment plans including MT and had high retention. Our FI incorporated criteria from a wide range of domains, including cognitive, emotional, quality of life, as well as physical performance criteria.
One limitation of the study is that a clinically meaningful FI score change has not been established. Rockwood et al 46, 47 did report mean FI scores for frailty categories based on other scales. For example, 0.22 was the mean FI score for people categorized as apparently vulnerable, and 0.27 was the mean FI score for people categorized as mildly frail on the Canadian Study of Health and Aging Clinical Frailty Scale. Individuals assigned to both categories have been shown to have worse survival than those in less frail categories. However, there was a large variance for FI scores within each category. 46 No minimum meaningful difference has yet been established for this continuous measurement to help guide interpretation of change. This represents an area for future research.
Another limitation is that this study was based in a single tertiary care center. Because the revascularization practices at this center may differ from other centers performing CABG and PCI, 48 generalizability may be limited. In addition, this study was not a randomized controlled trial. Some differences seen may be attributable to confounders not included in the analysis. In this population, mortality was too rare to include as an outcome in this analysis. The 3C study participants were younger and healthier than typical prospective cohorts included in frailty studies. Nevertheless, this analysis gives us important information about frailty at an early stage, when individuals may be less burdened by disabilities, but resilience is beginning to erode. Although this study is larger than many clinical prospective cohort studies of this type, it is smaller than some other community-based frailty studies. 
Conclusions
This study is one of the first to describe the different frailty trajectories for patients with CAD undergoing different approaches to their therapy. We found that frailty was more dynamic in frailer patients in this group. Women, older patients, and those undergoing CABG trended toward higher levels of frailty overall. In our sample, frailty followed a U-shaped curve after revascularization. However, relatively older patients (aged ≥75 years) initially assigned to MT or CABG did not experience this temporary decrease (or improvement). They showed continuous increases in their frailty level from baseline during the 30 months. If confirmed by other studies, frailty trajectories could be used to inform individualized decision making about initial treatment choices and allow more tailored subsequent patient care and monitoring once effective therapeutic approaches have been demonstrated. 2 Further research is needed to confirm our findings and extend them to more diverse patient populations. Examining frailty as a time-varying covariate within larger and longerterm studies would provide additional information about the differences in trajectories in terms of outcomes and provide a more nuanced context for possible interventions. A major gap in our current understanding of the management of frailty is the need for effective therapeutics. Studying the impact of interventions 49, 50 on frailty trajectories could speed up the development process and allow comparisons between studies and approaches.
